CHRS – Coherus BioSciences, Inc.
CHRS — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
20.61
Margin Of Safety %
Put/Call OI Ratio
0.11
EPS Next Q Diff
EPS Last/This Y
-2.17
EPS This/Next Y
-0.27
Price
1.27
Target Price
7.4
Analyst Recom
1.43
Performance Q
-27.84
Upside
-2,911.0%
Beta
0.93
Ticker: CHRS
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | CHRS | 1.475 | 0.15 | 0.00 | 13050 |
| 2026-07-14 | CHRS | 1.44 | 0.15 | 0.09 | 13079 |
| 2026-07-15 | CHRS | 1.43 | 0.15 | 0.00 | 13134 |
| 2026-07-16 | CHRS | 1.395 | 0.15 | 0.00 | 13145 |
| 2026-07-17 | CHRS | 1.41 | 0.15 | 0.04 | 13252 |
| 2026-07-20 | CHRS | 1.42 | 0.14 | 0.00 | 13228 |
| 2026-07-21 | CHRS | 1.48 | 0.14 | 3.71 | 13228 |
| 2026-07-22 | CHRS | 1.435 | 0.15 | 0.00 | 13380 |
| 2026-07-23 | CHRS | 1.44 | 0.16 | 0.00 | 13367 |
| 2026-07-24 | CHRS | 1.415 | 0.15 | 0.12 | 13645 |
| 2026-07-27 | CHRS | 1.465 | 0.15 | 0.00 | 13832 |
| 2026-07-28 | CHRS | 1.44 | 0.15 | 0.00 | 13832 |
| 2026-07-29 | CHRS | 1.41 | 0.15 | 0.71 | 13815 |
| 2026-07-30 | CHRS | 1.475 | 0.15 | 0.19 | 13837 |
| 2026-07-31 | CHRS | 1.4 | 0.15 | 0.00 | 14017 |
| 2026-08-03 | CHRS | 1.43 | 0.15 | 0.00 | 14129 |
| 2026-08-04 | CHRS | 1.48 | 0.14 | 0.26 | 14709 |
| 2026-08-05 | CHRS | 1.445 | 0.15 | 0.00 | 14972 |
| 2026-08-06 | CHRS | 1.265 | 0.15 | 0.03 | 15241 |
| 2026-08-07 | CHRS | 1.26 | 0.11 | 0.00 | 15308 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | CHRS | 1.47 | 66.2 | - | -0.74 |
| 2026-07-14 | CHRS | 1.44 | 66.2 | - | -0.74 |
| 2026-07-15 | CHRS | 1.43 | 66.2 | - | -0.74 |
| 2026-07-16 | CHRS | 1.39 | 66.2 | - | -0.74 |
| 2026-07-17 | CHRS | 1.40 | 66.2 | - | -0.74 |
| 2026-07-20 | CHRS | 1.42 | 66.2 | - | -0.74 |
| 2026-07-21 | CHRS | 1.48 | 66.2 | - | -0.74 |
| 2026-07-22 | CHRS | 1.43 | 66.2 | - | -0.74 |
| 2026-07-23 | CHRS | 1.43 | 66.2 | - | -0.74 |
| 2026-07-24 | CHRS | 1.41 | 66.2 | - | -0.74 |
| 2026-07-27 | CHRS | 1.46 | 66.2 | - | -0.74 |
| 2026-07-28 | CHRS | 1.45 | 66.2 | - | -0.74 |
| 2026-07-29 | CHRS | 1.41 | 66.2 | - | -0.74 |
| 2026-07-30 | CHRS | 1.48 | 66.2 | - | -0.74 |
| 2026-07-31 | CHRS | 1.40 | 66.2 | - | -0.74 |
| 2026-08-03 | CHRS | 1.44 | 66.2 | - | -0.74 |
| 2026-08-04 | CHRS | 1.44 | 66.2 | - | -0.74 |
| 2026-08-05 | CHRS | 1.45 | 66.2 | - | -0.74 |
| 2026-08-06 | CHRS | 1.26 | 66.2 | - | -0.74 |
| 2026-08-07 | CHRS | 1.27 | 66.2 | - | -0.74 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | CHRS | 0.00 | 6.25 | 22.41 |
| 2026-07-14 | CHRS | 0.00 | 6.25 | 22.41 |
| 2026-07-15 | CHRS | 0.00 | 6.25 | 22.41 |
| 2026-07-16 | CHRS | 0.00 | 6.25 | 22.41 |
| 2026-07-17 | CHRS | 0.00 | 6.25 | 22.41 |
| 2026-07-20 | CHRS | 0.00 | 6.02 | 22.41 |
| 2026-07-21 | CHRS | 0.00 | 6.02 | 22.41 |
| 2026-07-22 | CHRS | 0.00 | 6.02 | 22.41 |
| 2026-07-23 | CHRS | 0.00 | 6.02 | 22.41 |
| 2026-07-24 | CHRS | 0.00 | 6.02 | 22.41 |
| 2026-07-27 | CHRS | 0.00 | 5.19 | 20.61 |
| 2026-07-28 | CHRS | 0.00 | 5.19 | 20.61 |
| 2026-07-29 | CHRS | 0.00 | 5.19 | 20.61 |
| 2026-07-30 | CHRS | 0.00 | 5.19 | 20.61 |
| 2026-07-31 | CHRS | 0.00 | 5.19 | 20.61 |
| 2026-08-03 | CHRS | 0.00 | 4.03 | 20.61 |
| 2026-08-04 | CHRS | 0.00 | 4.03 | 20.61 |
| 2026-08-05 | CHRS | 0.00 | 4.03 | 20.61 |
| 2026-08-06 | CHRS | 0.00 | 4.03 | 20.61 |
| 2026-08-07 | CHRS | 0.00 | 4.03 | 20.61 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.22
Avg. EPS Est. Current Quarter
-0.12
Avg. EPS Est. Next Quarter
-0.23
Insider Transactions
Institutional Transactions
4.03
Beta
0.93
Average Sales Estimate Current Quarter
20
Average Sales Estimate Next Quarter
16
Fair Value
Quality Score
33
Growth Score
29
Sentiment Score
3
Actual DrawDown %
93.4
Max Drawdown 5-Year %
-96.5
Target Price
7.4
P/E
Forward P/E
PEG
P/S
3.85
P/B
3.22
P/Free Cash Flow
EPS
-1.02
Average EPS Est. Cur. Y
-0.74
EPS Next Y. (Est.)
-1.02
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-256.49
Relative Volume
1.49
Return on Equity vs Sector %
-100
Return on Equity vs Industry %
-100
EPS 1 7Days Diff
-0.5
EPS 1 30Days Diff
0.05
EBIT Estimation
◆
CHRS
Healthcare
$1.27
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
36.2
Range 1M
31.1%
Sup Dist
12.4%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
40.8%
EPS NY
33.6%
52W%
27.4%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+482.7% upside
Upside
+482.7%
Quality
33
CHRS — P/E HistoricalBiotechnology
Coherus Oncology, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 144
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. It also has a clinical collaboration agreement with Zumutor Biologics Inc. for the development of LOQTORZI with ZM0008 as a treatment for cancer patients. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
CHRS
Latest News
—
Caricamento notizie per CHRS…
stock quote shares CHRS – Coherus BioSciences, Inc. Stock Price stock today
news today CHRS – Coherus BioSciences, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CHRS – Coherus BioSciences, Inc. yahoo finance google finance
stock history CHRS – Coherus BioSciences, Inc. invest stock market
stock prices CHRS premarket after hours
ticker CHRS fair value insiders trading